Storia in 7 fonti

Novartis says buoyed by new treatments in second quarter

Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products.

Raccontata dabiopharmadive.comfrance24.commilanofinanza.itvalor.globo.combenzinga.cominvestors.comnzz.ch

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

france24.comStai leggendo1 g fa

Novartis says buoyed by new treatments in second quarter

Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products.

originale

biopharmadive.com1 g fa

Novartis climbs on upbeat drug sales as key readouts loom

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

Leggi questa versione → originale

benzinga.com1 g fa

Why Is Novartis Stock Gaining Tuesday? - Novartis (NYSE:NVS)

Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

Leggi questa versione → originale

milanofinanza.it1 g fa

Novartis supera le attese, BofA conferma buy: i 5 studi clinici di fase III da seguire nel secondo semestre…

Migliori del previsto i ricavi a 14,4 miliardi di dollari e l’utile operativo a 5,94 miliardi nel secondo trimestre. La guidance 2026 poteva essere alzata secondo gli analisti

Leggi questa versione → originale

investors.com1 g fa

Novartis Bounds For Buy Point; Why Shares Are On The Rise

Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.

Leggi questa versione → originale

valor.globo.com1 g fa

Novartis supera estimativas no 2º trimestre, mas mantém cautela nas estimativas

A gigante farmacêutica suíça registrou vendas líquidas de US$ 14,41 bilhões, um avanço de 1% na comparação anual, superando a estimativa de US$ 13,96 bilhões do consenso da Visible Alpha

Leggi questa versione → originale

Timeline cronologica

1. martedì 21 luglio 2026·biopharmadive.com
   

   Novartis climbs on upbeat drug sales as key readouts loom

   A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

2. martedì 21 luglio 2026·france24.com
   

   Novartis says buoyed by new treatments in second quarter

   Swiss pharmaceuticals giant Novartis said Tuesday that group sales exceeded expectations in the second quarter of 2026, on the back of a range of new products.

3. martedì 21 luglio 2026·milanofinanza.it
   

   Novartis supera le attese, BofA conferma buy: i 5 studi clinici di fase III da seguire nel secondo semestre 2026 | MilanoFinanza News

   Migliori del previsto i ricavi a 14,4 miliardi di dollari e l’utile operativo a 5,94 miliardi nel secondo trimestre. La guidance 2026 poteva essere alzata secondo gli analisti

4. martedì 21 luglio 2026·valor.globo.com
   

   Novartis supera estimativas no 2º trimestre, mas mantém cautela nas estimativas

   A gigante farmacêutica suíça registrou vendas líquidas de US$ 14,41 bilhões, um avanço de 1% na comparação anual, superando a estimativa de US$ 13,96 bilhões do consenso da…

5. martedì 21 luglio 2026·benzinga.com
   

   Why Is Novartis Stock Gaining Tuesday? - Novartis (NYSE:NVS)

   Novartis shares rise as strong Q2 demand for key growth drugs offsets generic competition. NVS beats Q2 earnings and reaffirms 2026 targets.

6. martedì 21 luglio 2026·investors.com
   

   Novartis Bounds For Buy Point; Why Shares Are On The Rise

   Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.

7. martedì 21 luglio 2026·nzz.ch
   

   Der Pharmakonzern Novartis verjüngt sein Geschäft geschickt

   Trotz hohen Einbussen beim nicht mehr patentgeschützten Herzmittel Entresto ist Novartis schon wieder auf Wachstumskurs. An der Börse dürfte es für den Konzern im zweiten Semester…